The universal quorum sensing autoinducer, AI-2, is utilized by several bacteria. Analogs of AI-2 have the potential to modulate bacterial behavior. Selectively quenching the communication of a few bacteria, in the presence of several others in an ecosystem, using analogs of AI-2 is non-trivial due to the ubiquity of AI-2 processing receptors in many bacteria that co-exist. Herein, we demonstrate that when an AI-2 analog, isobutyl DPD (which has been previously shown to be a quorum sensing, QS, quencher in both Escherichia coli and Salmonella typhimurium) is modified with ester groups, which get hydrolyzed once inside the bacterial cells, only QS in E. coli, but not in S. typhimurium, is inhibited. The origin of this differential QS inhibition could be due to differences in analog permeation of the bacterial membranes or ester hydrolysis rates. Such differences could be utilized to selectively target QS in specific bacteria amongst a consortium of other species that also use AI-2 signaling.
30 September 2026 in Beilstein Journal of Organic Chemistry
Heterocyclic compounds are often considered privileged scaffolds because many bioactive molecules contain these moieties. Several inhibitors of the valosin-containing protein (VCP, also known as p97), a target for cancer therapeutics, contain 5 or 6-membered heterocyclic cores. With the rise of resistance among these VCP inhibitors, we propose a new class of heterocycles as potential cancer therapeutics. The Groebke–Blackburn–Bienaymé (GBB) reaction is a classic method to produce imidazole compounds. In our earlier study, we showed that acyclic amidines can effectively produce trisubstituted imidazoles known as benzyl imine tricyclic imidazoles (BITIs) via this multicomponent reaction. Herein, we report the first systematic evaluation of para -substituted benzamidines produced via the microwave-assisted GBB reaction, which enables the tuning of trisubstituted imidazole compounds and their application as VCP inhibitors. Several of the newly developed compounds inhibit VCP activity, with one amidinopyridine derivative showing low-micromolar, cancer-selective cytotoxicity. This establishes a new scaffold for VCP inhibitor development.